Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CD19 CAR-T in Relapsed/Refractory Lymphoma
NCT03488160Unknown
- Sponsor
- Sinobioway Group Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Open-label, single-arm trial of Sino19 in B cell lymphoma, sponsored by Sinobioway Group Co., Ltd. Primary endpoint: Overall efficiency at 3 years. Status: unknown.
02
Drugs
Sino19
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT03488160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03488160.